Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017


Real-time Estimate Quote. Real-time Estimate Tradegate - 09/23 03:59:57 pm
54.71 EUR   +1.58%
09/21BAYER : opens application window for Grants4Ag
09/18GLOBAL MARKETS LIVE : Tiktok, CaixaBank, Moderna…
09/18Covestro denies it is in takeover talks with Apollo
SummaryAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer Executive Joins Johnson & Johnson as CIO

share with twitter share with LinkedIn share with facebook
10/03/2019 | 02:47pm EDT

By Sara Castellanos

Jim Swanson, formerly a technology executive at Bayer AG's crop-science division, has joined Johnson & Johnson as chief information officer.

He succeeds Stuart McGuigan, who was CIO at J&J for seven years and now runs information technology at the State Department.

Mr. Swanson will be responsible for "amplifying Johnson & Johnson's business impact and shaping its direction through the strategic use of technology," according to a company biography. J&J declined to comment and Mr. Swanson couldn't be reached for comment.

At Bayer, Mr. Swanson led initiatives that involved data science -- generating insights or predictions from data using algorithms. In one example, he used data science to reduce the crop-science division's carbon footprint, according to a video on Bayer's website.

J&J Chief Executive Alex Gorsky spoke about the strategic importance of data science on an earnings call in May: "We're spending a lot of time looking at data-science capabilities and how we integrate that more and more into what we're doing on a daily basis in pharma."

The company makes prescription drugs, medical devices, consumer goods such as Band-Aids and baby shampoo, and other products.

Mr. Swanson joins J&J at a time when the health-care industry is betting on emerging technologies such as artificial intelligence and predictive analytics to identify patients at risk for opioid abuse and chronic diseases, said Ana Gupte, an independent health-care analyst. The drugmaker this week agreed to a $20.4 million settlement to avoid a trial accusing the company of helping spark an opioid-addiction crisis in two Ohio counties.

Ms. Gupte said that health-care companies are also using emerging technologies to help physicians improve the accuracy of various diagnoses and to advance the development of drugs. "Artificial intelligence and machine learning are pretty critical for a company like J&J," she said.

Mr. Swanson has a reputation for being a solid manager and technology leader, said Gerry McNamara, senior partner for the technology officers practice at executive-search firm Korn Ferry. "He's a very highly collaborative team player, thoughtful on the field with his people and rolls up his sleeves when necessary," Mr. McNamara said. Korn Ferry wasn't involved in Mr. Swanson's recruitment.

At J&J, Mr. Swanson is based at the drugmaker's headquarters in New Brunswick, N.J. At Bayer, he was based in Monheim, Germany, according to the company's website. The new CIO at Bayer's crop-science unit is Ingo Elfering, formerly CIO and innovation officer at U.K.-based drugmaker Indivior PLC.

Before joining Bayer, Mr. Swanson was CIO at seed and pesticide company Monsanto, acquired by Bayer for $63 billion in 2018.

Between 1996 and 2005, Mr. Swanson was an IT executive at J&J's research-and-development division. He has a bachelor's degree in bioscience and biotechnology as well as a master's degree in computer science, both from Drexel University.

Write to Sara Castellanos at sara.castellanos@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG 2.04% 54.96 Delayed Quote.-26.03%
COLUMBIA SPORTSWEAR COMPANY 0.77% 89.99 Delayed Quote.-10.87%
JOHNSON & JOHNSON 0.16% 144.44 Delayed Quote.-1.14%
NEXT PLC 2.00% 6110 Delayed Quote.-14.65%
TEAM, INC. -5.31% 5.71 Delayed Quote.-62.24%
share with twitter share with LinkedIn share with facebook
All news about BAYER AG
09/21BAYER : opens application window for Grants4Ag
09/18GLOBAL MARKETS LIVE : Tiktok, CaixaBank, Moderna…
09/18Covestro denies it is in takeover talks with Apollo
09/17EXCLUSIVE : In the weeds - How Bayer, U.S. government teamed up against Thailand..
09/17IN THE WEEDS : How Bayer, U.S. govt teamed up against Thailand's glyphosate ban
09/17BAYER : New data reinforce strong clinical profile of Vitrakvi™ for patien..
09/15BAYER : settles thousands of U.S. Roundup cases with trial attorneys
09/15Bayer settles thousands of U.S. Roundup cases with trial attorneys
09/15BAYER : Signs $25 Million License Agreement With US Company to Develop Breast Ca..
09/15BAYER : and Systems Oncology sign exclusive license agreement on innovative brea..
More news
Sales 2020 43 305 M 50 492 M 50 492 M
Net income 2020 -2 690 M -3 136 M -3 136 M
Net Debt 2020 32 651 M 38 070 M 38 070 M
P/E ratio 2020 -16,4x
Yield 2020 5,17%
Capitalization 53 994 M 63 077 M 62 954 M
EV / Sales 2020 2,00x
EV / Sales 2021 1,92x
Nbr of Employees 101 168
Free-Float 100,0%
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 78,72 €
Last Close Price 54,96 €
Spread / Highest target 100%
Spread / Average Target 43,2%
Spread / Lowest Target -16,3%
EPS Revisions
Werner Baumann Chairman-Management Board
Norbert Winkeljohann Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-26.03%61 959
JOHNSON & JOHNSON-1.14%379 679
ROCHE HOLDING AG8.39%315 948
MERCK & CO., INC.-8.81%209 775
PFIZER, INC.-8.07%201 437
NOVARTIS AG-11.13%195 696